METHOTREXATE IN SARCOIDOSIS: HEMATOLOGIC AND HEPATIC TOXICITY ENCOUNTERED IN A LARGE COHORT OVER A SIX YEAR PERIOD

Robert P. Baughman; Johanna P. Cremers; Martina Harmon; Elyse E. Lower; Marjolein Drent

doi:10.36141/svdld.v37i3.9362

METHOTREXATE IN SARCOIDOSIS: HEMATOLOGIC AND HEPATIC TOXICITY ENCOUNTERED IN A LARGE COHORT OVER A SIX YEAR PERIOD

Robert P. Baughman^*, Johanna P. Cremers, Martina Harmon, Elyse E. Lower, Marjolein Drent

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Web of Science)

Abstract

Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long term safety and efficacy in sarcoidosis remains unclear. Methods: This was a retrospective review of patients seen at the University of Cincinnati Sarcoidosis Clinic over a six year period. For each visit, complete blood count, liver function testing, and dosing and outcome of MTX was noted. For efficacy, we compared the outcome of therapy of a matching subgroup of patients treated with either MTX or infliximab for one year and results scored as improved, stable, or worse based on response of the target organ. Results: Over six years, 1606 sarcoidosis patients were seen with a total of 13,576 clinical visits. During the study period, 607 patients (38% of total) were receiving MTX and had available blood work. Moderate elevation of alanine aminotransferase (ALT) (>3 times upper limit normal) was seen in nine (1.6%) patients. White blood count of

Original language	English
Article number	2020001
Number of pages	10
Journal	Sarcoidosis Vasculitis and Diffuse Lung Diseases
Volume	37
Issue number	3
DOIs	https://doi.org/10.36141/svdld.v37i3.9362
Publication status	Published - 2020

Keywords

sarcoidosis
methtorexate
liver function tests
leukopenia
infliximab
LOW-DOSE METHOTREXATE
RHEUMATOID-ARTHRITIS
DOUBLE-BLIND
PULMONARY SARCOIDOSIS
LIVER-DAMAGE
RISK-FACTORS
THERAPY
EFFICACY
RECOMMENDATIONS
LEFLUNOMIDE

Access to Document

10.36141/svdld.v37i3.9362

Cite this

@article{12029bbd473041bc8b7d2cfb52648bae,

title = "METHOTREXATE IN SARCOIDOSIS: HEMATOLOGIC AND HEPATIC TOXICITY ENCOUNTERED IN A LARGE COHORT OVER A SIX YEAR PERIOD",

abstract = "Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long term safety and efficacy in sarcoidosis remains unclear. Methods: This was a retrospective review of patients seen at the University of Cincinnati Sarcoidosis Clinic over a six year period. For each visit, complete blood count, liver function testing, and dosing and outcome of MTX was noted. For efficacy, we compared the outcome of therapy of a matching subgroup of patients treated with either MTX or infliximab for one year and results scored as improved, stable, or worse based on response of the target organ. Results: Over six years, 1606 sarcoidosis patients were seen with a total of 13,576 clinical visits. During the study period, 607 patients (38% of total) were receiving MTX and had available blood work. Moderate elevation of alanine aminotransferase (ALT) (>3 times upper limit normal) was seen in nine (1.6%) patients. White blood count of",

keywords = "sarcoidosis, methtorexate, liver function tests, leukopenia, infliximab, LOW-DOSE METHOTREXATE, RHEUMATOID-ARTHRITIS, DOUBLE-BLIND, PULMONARY SARCOIDOSIS, LIVER-DAMAGE, RISK-FACTORS, THERAPY, EFFICACY, RECOMMENDATIONS, LEFLUNOMIDE",

author = "Baughman, {Robert P.} and Cremers, {Johanna P.} and Martina Harmon and Lower, {Elyse E.} and Marjolein Drent",

year = "2020",

doi = "10.36141/svdld.v37i3.9362",

language = "English",

volume = "37",

journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",

issn = "1124-0490",

publisher = "Mattioli 1885 S.p.A.",

number = "3",

}

TY - JOUR

T1 - METHOTREXATE IN SARCOIDOSIS

T2 - HEMATOLOGIC AND HEPATIC TOXICITY ENCOUNTERED IN A LARGE COHORT OVER A SIX YEAR PERIOD

AU - Baughman, Robert P.

AU - Cremers, Johanna P.

AU - Harmon, Martina

AU - Lower, Elyse E.

AU - Drent, Marjolein

PY - 2020

Y1 - 2020

N2 - Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long term safety and efficacy in sarcoidosis remains unclear. Methods: This was a retrospective review of patients seen at the University of Cincinnati Sarcoidosis Clinic over a six year period. For each visit, complete blood count, liver function testing, and dosing and outcome of MTX was noted. For efficacy, we compared the outcome of therapy of a matching subgroup of patients treated with either MTX or infliximab for one year and results scored as improved, stable, or worse based on response of the target organ. Results: Over six years, 1606 sarcoidosis patients were seen with a total of 13,576 clinical visits. During the study period, 607 patients (38% of total) were receiving MTX and had available blood work. Moderate elevation of alanine aminotransferase (ALT) (>3 times upper limit normal) was seen in nine (1.6%) patients. White blood count of

AB - Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long term safety and efficacy in sarcoidosis remains unclear. Methods: This was a retrospective review of patients seen at the University of Cincinnati Sarcoidosis Clinic over a six year period. For each visit, complete blood count, liver function testing, and dosing and outcome of MTX was noted. For efficacy, we compared the outcome of therapy of a matching subgroup of patients treated with either MTX or infliximab for one year and results scored as improved, stable, or worse based on response of the target organ. Results: Over six years, 1606 sarcoidosis patients were seen with a total of 13,576 clinical visits. During the study period, 607 patients (38% of total) were receiving MTX and had available blood work. Moderate elevation of alanine aminotransferase (ALT) (>3 times upper limit normal) was seen in nine (1.6%) patients. White blood count of

KW - sarcoidosis

KW - methtorexate

KW - liver function tests

KW - leukopenia

KW - infliximab

KW - LOW-DOSE METHOTREXATE

KW - RHEUMATOID-ARTHRITIS

KW - DOUBLE-BLIND

KW - PULMONARY SARCOIDOSIS

KW - LIVER-DAMAGE

KW - RISK-FACTORS

KW - THERAPY

KW - EFFICACY

KW - RECOMMENDATIONS

KW - LEFLUNOMIDE

U2 - 10.36141/svdld.v37i3.9362

DO - 10.36141/svdld.v37i3.9362

M3 - Article

C2 - 33264378

VL - 37

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

IS - 3

M1 - 2020001

ER -